Saracatinib

Generic Name
Saracatinib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C27H32ClN5O5
CAS Number
379231-04-6
Unique Ingredient Identifier
9KD24QGH76
Background

Saracatinib has been investigated for the treatment of Cancer, Osteosarcoma, Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer.

Associated Conditions
-
Associated Therapies
-

SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis

First Posted Date
2018-09-07
Last Posted Date
2019-08-13
Lead Sponsor
King's College London
Target Recruit Count
30
Registration Number
NCT03661125
Locations
πŸ‡¬πŸ‡§

Mitul Mehta, London, Camberwell, United Kingdom

Saracatinib and Alcohol Drinking

Phase 2
Completed
Conditions
Interventions
First Posted Date
2016-11-04
Last Posted Date
2020-11-13
Lead Sponsor
Yale University
Target Recruit Count
50
Registration Number
NCT02955186
Locations
πŸ‡ΊπŸ‡Έ

CMHC, Substance Abuse Center, New Haven, Connecticut, United States

Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2016-04-13
Last Posted Date
2020-07-30
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
28
Registration Number
NCT02737202
Locations
πŸ‡ΊπŸ‡Έ

Laboratory of Translational Research NHLBI, Bethesda, Maryland, United States

πŸ‡ΊπŸ‡Έ

Baylor College of Medicine - Ben Taub General Hospital, Houston, Texas, United States

πŸ‡ΊπŸ‡Έ

University of Cincinnati, Cincinnati, Ohio, United States

and more 2 locations

Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-04-08
Last Posted Date
2020-01-14
Lead Sponsor
Yale University
Target Recruit Count
5
Registration Number
NCT02732587
Locations
πŸ‡ΊπŸ‡Έ

CMHC, Substance Abuse Center, New Haven, Connecticut, United States

The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-04-17
Last Posted Date
2016-11-30
Lead Sponsor
Tony Eissa
Target Recruit Count
9
Registration Number
NCT02116712
Locations
πŸ‡ΊπŸ‡Έ

University of Texas Health Science Center-Houston, Houston, Texas, United States

πŸ‡ΊπŸ‡Έ

Baylor College of Medicine, Houston, Texas, United States

πŸ‡ΊπŸ‡Έ

University of Cincinnati, Cincinnati, Ohio, United States

SarCaBon: A Randomised Phase II Trial of Saracatinib Versus Placebo for Cancer-induced Bone Pain

Phase 2
Completed
Conditions
Interventions
First Posted Date
2014-03-13
Last Posted Date
2018-04-13
Lead Sponsor
Sheffield Teaching Hospitals NHS Foundation Trust
Target Recruit Count
12
Registration Number
NCT02085603
Locations
πŸ‡¬πŸ‡§

Sheffield Teaching Hospitals NHS Trust, Sheffield, South Yorkshire, United Kingdom

Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease

Phase 1
Completed
Conditions
Interventions
First Posted Date
2013-05-29
Last Posted Date
2021-04-23
Lead Sponsor
Stephen M. Strittmatter
Target Recruit Count
24
Registration Number
NCT01864655
Locations
πŸ‡ΊπŸ‡Έ

Yale Alzheimer's Disease Research Unit, New Haven, Connecticut, United States

Saracatinib in Treating Patients With Prostate Cancer

First Posted Date
2010-12-28
Last Posted Date
2015-04-01
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
31
Registration Number
NCT01267266
Locations
πŸ‡ΊπŸ‡Έ

University of Chicago, Chicago, Illinois, United States

πŸ‡ΊπŸ‡Έ

University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States

πŸ‡ΊπŸ‡Έ

Decatur Memorial Hospital, Decatur, Illinois, United States

and more 12 locations

Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer

First Posted Date
2010-09-08
Last Posted Date
2015-05-05
Lead Sponsor
University College, London
Target Recruit Count
107
Registration Number
NCT01196741
Locations
πŸ‡¬πŸ‡§

St Bartholomew's Hospital, London, Greater London, United Kingdom

πŸ‡¬πŸ‡§

The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom

πŸ‡¬πŸ‡§

University College London Hospital, London, Greater London, United Kingdom

and more 9 locations

A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2008-09-15
Last Posted Date
2020-01-18
Lead Sponsor
Sarcoma Alliance for Research through Collaboration
Target Recruit Count
38
Registration Number
NCT00752206
Locations
πŸ‡ΊπŸ‡Έ

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

πŸ‡ΊπŸ‡Έ

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

πŸ‡ΊπŸ‡Έ

UCLA/Mattel's Children's Hospital, Los Angeles, California, United States

and more 15 locations
Β© Copyright 2024. All Rights Reserved by MedPath